Accuracy of Clinical Staging and Outcome With Primary Resection for Local-Regionally Limited Esophageal Adenocarcinoma. Issue 3 (March 2018)

• Record Type: Journal Article
• Authors: Worrell, Stephanie G.; Alicuben, Evan T.; Oh, Daniel S.; Hagen, Jeffrey A.; DeMeester, Steven R.
• Is Part Of: Annals of surgery. Volume 267:Issue 3(2018:Mar.)
• Publication Date: 2018-03
• Subjects: clinical staging -- esophageal adenocarcinoma esophagectomy -- endoscopic resection -- neoadjuvant therapy; Surgery -- Periodicals; 617.005
• DOI: 10.1097/SLA.0000000000002139
• Languages: English
• ISSNs: 0003-4932

Abstract

Abstract : Objective: The aim of this study was to determine the accuracy of clinical staging, to assess survival with surgical resection alone, and to determine factors associated with understaging in patients with esophageal adenocarcinoma thought to have limited local-regional disease. Background: Primary surgical resection is the preferred treatment in patients with esophageal adenocarcinoma clinically staged to have limited nodal disease. This approach requires reliable clinical staging. Methods: A retrospective chart review was performed of all patients who had primary esophagectomy for clinical stage T1–3 N0–1 adenocarcinoma (seventh edition AJCC) from January 2002 to May 2013. Clinical and pathologic stages were compared and overall survival was analyzed. Results: There were 88 patients who met inclusion criteria. Final pathology confirmed appropriate clinical staging (⩽T3N1) in 76% of patients (67/88). There were 21 patients who were understaged (>T3N1), and in all cases, understaging was based on the presence of advanced nodal (N2 or N3) disease. Factors independently associated with understaging were the presence of dysphagia, tumor length >3 cm, and poor differentiation. At a median follow-up of 35 months, 63% of all patients (55/88) remain alive. The 5-year survival in correctly staged patients was 67%, compared with 33% for those who were understaged ( P < 0.0001). Conclusions: Modern clinical staging will accurately identify the majority of patients with esophageal adenocarcinoma and limited local-regional disease (⩽pT3N1). Survival with surgery alone in correctly staged patients was excellent and unlikely to be improved with neoadjuvant therapy. A combination of dysphagia, poor differentiation, and tumor length >3 cm was associated with understaging in 92% of patients. Patients with these factors are likely to have more advanced disease than clinically suspected and may benefit from neoadjuvant therapy before resection.